#SGO2025
LightNews LightNews
onclive.bsky.social
Kicking off day 1 of the 2025 SGO Winter Meeting strong! #SGO2025 #gyncsm. Check back on onclive.com/conference/s... for insights from these great presentations
January 30, 2025 at 6:13 PM
peerview.bsky.social
How can you maximize the use of PARP inhibitors, immunotherapy, & ADCs? Join us at Seattle Convention Center – Ballroom 6E during #SGO2025 for expert insights from Drs. Moore, O’Malley & Pothuri. 📅 Mar 15 | 7:15 AM PDT
🔗 Register now: bit.ly/GynOnc25sky foundationforwomenscancer.org
#medsky #oncsky
March 5, 2025 at 9:15 PM
roswellpark.bsky.social
Sarah Werner, MD, and Nicole Gaulin, MD, will be presenting at the #SGO2025 Annual Meeting on Women’s Cancer!

This gathering brings together experts in #gynecologiconcology to collaborate, network, & explore groundbreaking science that’s shaping the future of care for patients.
March 14, 2025 at 4:09 PM
cancertherapyadv.bsky.social
Mirvetuximab soravtansine improved OS vs chemo in patients with FRα+, platinum-resistant ovarian cancer in the MIRASOL trial. Data were presented at #SGOMtg by Dr Toon Van Gorp of @uzleuven.bsky.social. #SGO2025 #gyncsm shorturl.at/n4n3o
March 17, 2025 at 4:02 PM
onclive.bsky.social
Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer #SGO2025

www.onclive.com/view/avutome...
Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer
The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.
www.onclive.com
March 17, 2025 at 8:06 PM
onclive.bsky.social
Good morning Seattle! 🌆

☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!

#SGOMtg #AM25IMPACT #gynsm
March 15, 2025 at 1:30 PM
onclive.bsky.social
Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC @mdanderson.bsky.social #SGO2025
www.onclive.com/view/pembrol...
Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC
The combination of pembrolizumab and lenvatinib showed promising activity including durable responses in patients with platinum-resistant HGSOC.
www.onclive.com
March 17, 2025 at 3:32 PM
onclive.bsky.social
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 www.onclive.com/view/olapari...
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer
Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.
www.onclive.com
March 15, 2025 at 4:53 PM
pearlf.bsky.social
"Matt Hellmann [VP Early Oncology Dev] told @endpts.com
in interview that there have been very few advances in 2nd-line endometrial cancer over the past several decades. For context, chemotherapy currently produces a response rate in the 20% range & a PFS of 4 to 5 months, he said" #gynsm #SGO2025
pearlf.bsky.social Pearl Freier @pearlf.bsky.social · Mar 17
Encouraging clinical trial data from AstraZeneca & ADC in metastatic endometrial cancer: 2 mg/kg dose of puxitatug samrotecan/P-sam achieved a 34.6% objective response rate in patients w/ B7-H4 positive advanced or metastatic endometrial cancer in Phase 1/2a trial. endpts.com/astrazeneca-... 1/n
March 17, 2025 at 2:04 PM
cancertherapyadv.bsky.social
DB-1305/BNT325 demonstrated durable activity in patients with previously treated ovarian cancer, according to data presented at #SGOMtg by Dr Maria Rubinstein of @mskcancercenter.bsky.social. #SGO2025 #gyncsm shorturl.at/tA2bw
Antibody-Drug Conjugate Proves Active in Ovarian Cancer
A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer.
shorturl.at
March 16, 2025 at 9:13 PM
onclive.bsky.social
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #ovca #gyncsm www.onclive.com/view/updated...
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.
www.onclive.com
March 16, 2025 at 5:11 PM
onclive.bsky.social
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/nivolum...
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer
Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.
www.onclive.com
March 15, 2025 at 3:25 PM
sitemancenter.bsky.social
The Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer takes place this weekend, featuring presentations by @washumedicine.bsky.social physicians Matthew Powell, MD, and Lindsay Kuroki, MD. #SGOMtg #AM25IMPACT #SGO2025

Learn more: bit.ly/4hsHDOR
March 13, 2025 at 9:25 PM
pearlf.bsky.social
The 2.4 mg/kg dose hit a 38.5% ORR, according to data presented Saturday at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Seattle. #SGO2025 #gynsm endpts.com/astrazeneca-...
AstraZeneca reveals first-in-human data for B7-H4-targeting ADC in endometrial cancer
AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response and survival results in endometrial cancer patients enrolled in an early s...
endpts.com
March 17, 2025 at 2:02 PM
roswellpark.bsky.social
Learn more about #SGO2025: www.sgo.org.
Society of Gynecologic Oncology
The Society of Gynecologic Oncology (SGO) is the world’s premier organization for everyone who works to cure gynecologic cancers.
www.sgo.org
March 14, 2025 at 4:09 PM
cancer-vaccine.activitypub.awakari.com.ap.brid.gy
BVAC-C Vaccine Therapy Plus Durvalumab Elicits Responses in Recurrent HPV+ Cervical Cancer BVAC-C...

https://www.mashupmd.com/bvac-c-vaccine-therapy-plus-durvalumab-elicits-responses-in-recurrent-hpv-cervical-cancer/

#General #Medicine #News #CervicalCancer,SGO2025

Event Attributes
BVAC-C Vaccine Therapy Plus Durvalumab Elicits Responses in Recurrent HPV+ Cervical Cancer
BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer. Read the full article here
www.mashupmd.com
April 10, 2025 at 6:11 AM
onclive.bsky.social
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer #SGO2025 #gynsm #oncology www.onclive.com/view/dual-pd...
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer
Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.
www.onclive.com
April 8, 2025 at 1:08 PM
onclive.bsky.social
Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/pamipar...
Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.
www.onclive.com
March 17, 2025 at 9:42 PM
onclive.bsky.social
Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer @danafarber.bsky.social #SGOMtg #SGO2025 #gyncsm
www.onclive.com/view/rina-s-...
Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer
The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.
www.onclive.com
March 17, 2025 at 9:23 PM
onclive.bsky.social
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer #SGO2025 #SGOMtg #gyncsm

www.onclive.com/view/dostarl...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.
www.onclive.com
March 17, 2025 at 6:17 PM
onclive.bsky.social
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
#SGO2025 #SGOMtg #gyncsm
www.onclive.com/view/real-wo...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.
www.onclive.com
March 17, 2025 at 6:03 PM
onclive.bsky.social
Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/metform...
Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.
www.onclive.com
March 17, 2025 at 3:59 PM
onclive.bsky.social
Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer #SGOMtg #SGO2025 #ovca

www.onclive.com/view/frontli...
Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer
Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.
www.onclive.com
March 16, 2025 at 9:09 PM
onclive.bsky.social
Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer @pennmedicine.bsky.social #gyncsm #SGOMtg #SGO2025
www.onclive.com/view/cyclin-...
Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer
Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.
www.onclive.com
March 16, 2025 at 4:47 PM
onclive.bsky.social
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer #SGOMtg #AM25IMPACT #SGO2025 #oncology #gyncsm
www.onclive.com/view/zimbere...
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer
The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.
www.onclive.com
March 15, 2025 at 8:17 PM